US Bancorp
FDMT icon

US Bancorp’s 4D Molecular Therapeutics FDMT Stock Holding History

US Bancorp’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$771 Buy
58
+23
+66% +$224 ﹤0.01% 4007
2026
Q1 		$326 Buy
+35
New +$305 ﹤0.01% 4046
2025
Q4 		– Sell
-57
Closed -$495 – 4095
2025
Q3 		$495 Buy
+57
New +$341 ﹤0.01% 3873
2025
Q1 		– Sell
-247
Closed -$1.38K – 4259
2024
Q4 		$1.38K Sell
247
-755
-75% -$5.92K ﹤0.01% 3917
2024
Q3 		$10.8K Sell
1,002
-102
-9% -$1.69K ﹤0.01% 3348
2024
Q2 		$23.2K Sell
1,104
-756
-41% -$19K ﹤0.01% 3009
2024
Q1 		$59.3K Buy
1,860
+63
+4% +$1.61K ﹤0.01% 2599
2023
Q4 		$36.4K Buy
1,797
+1,533
+581% +$20.2K ﹤0.01% 2825
2023
Q3 		$3.36K Hold
264
– – ﹤0.01% 3545
2023
Q2 		$4.77K Buy
+264
New +$4.86K ﹤0.01% 3490
2023
Q1 		– Sell
-113
Closed -$2.51K – 4123
2022
Q4 		$2.51K Sell
113
-259
-70% -$4K ﹤0.01% 3718
2022
Q3 		$3K Sell
372
-352
-49% -$3.19K ﹤0.01% 3729
2022
Q2 		$5K Sell
724
-680
-48% -$6.61K ﹤0.01% 3580
2022
Q1 		$21K Buy
1,404
+695
+98% +$10.9K ﹤0.01% 3043
2021
Q4 		$16K Buy
709
+391
+123% +$9.58K ﹤0.01% 3230
2021
Q3 		$9K Buy
318
+298
+1,490% +$8.5K ﹤0.01% 3473
2021
Q2 		$0 Buy
+20
New +$612 ﹤0.01% 4018

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

US Bancorp's FDMT Position: Q2 2026 in Review

US Bancorp increased its 4D Molecular Therapeutics (FDMT) stake by 66% in Q2 2026, buying an estimated $224 and bringing the position to 58 shares worth $771. The position accounts for ﹤0.01% of the portfolio, ranked #4007.

US Bancorp first reported a position in FDMT in Q2 2021 and has held it in 17 quarters since. The position peaked at $59.3K in Q1 2024. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • US Bancorp held 58 shares of 4D Molecular Therapeutics worth $771 as of Q2 2026.
  • US Bancorp bought 23 4D Molecular Therapeutics shares in Q2 2026, an estimated $224.
  • 4D Molecular Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #4007 holding.
  • US Bancorp first reported a position in 4D Molecular Therapeutics in Q2 2021 and has held it in 17 quarters since.
  • US Bancorp's 4D Molecular Therapeutics position peaked at $59.3K in Q1 2024.
  • 157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.